Validation of a flow cytometry based G2M delay cell cycle assay for use in evaluating the pharmacodynamic response to Aurora A inhibition
Authors:
- Jose EstevamJEJose Estevam
- Hadi DanaeeHDHadi Danaee
- Ray LiuRLRay Liu
- Jeffrey EcsedyJEJeffrey Ecsedy
- William L. TrepicchioWTWilliam L. Trepicchio
- Timothy WyantTWTimothy Wyant
- 1 January 2011
- journal article
- research article
- Published by Elsevier in Journal of Immunological Methods
- Vol. 363 (2) , 135-142
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Aurora Kinases as Anticancer Drug TargetsClinical Cancer Research, 2008
- Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeuticsJournal of Immunological Methods, 2007
- Key elements of bioanalytical method validation for small moleculesThe AAPS Journal, 2007
- Roles of Aurora Kinases in Mitosis and TumorigenesisMolecular Cancer Research, 2007
- Aurora Kinases: New Targets for Cancer TherapyClinical Cancer Research, 2006
- Aurora-kinase inhibitors as anticancer agentsNature Reviews Cancer, 2004
- The Aurora kinases: Role in cell transformation and tumorigenesisCancer and Metastasis Reviews, 2003
- Mitotic mechanics: the auroras come into viewCurrent Opinion in Cell Biology, 2003
- Recommendations for the Bioanalytical Method Validation of Ligand-Binding Assays to Support Pharmacokinetic Assessments of MacromoleculesPharmaceutical Research, 2003
- Validation of immunoassays for bioanalysis: a pharmaceutical industry perspectiveJournal of Pharmaceutical and Biomedical Analysis, 2000